MedTrace Logo

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

NCT07268040 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-01-12

No results posted yet for this study

Summary

This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.

Conditions

  • Malignant Solid Tumors

Interventions

DRUG

SHR-7787 Injection

SHR-7787 Injection.

DRUG

SHR-1316 Injection

SHR-1316 Injection.

DRUG

SHR-4849 Injection

SHR-4849 Injection.

DRUG

Etoposide injection

Etoposide Injection.

DRUG

Carboplatin injection

Carboplatin Injection.

DRUG

Cisplatin injection

Cisplatin Injection.

DRUG

BP102 Injection

BP102 Injection.

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-23
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07268040 on ClinicalTrials.gov